Novel organic proteasome inhibitors identified by virtual and in vitro screening

Proteasome inhibition is a promising strategy for treating cancers. Herein, we report the discovery of novel drug-like inhibitors of mammalian proteasome 20S using a multistep structure-based virtual ligand screening strategy. Sulfone- or piperazine-containing hits essentially belong to the under-represented class of noncovalent and nonpeptidic proteasome inhibitors. Several of our compounds act in the micromolar range and are cytotoxic on human tumoral cell lines. Optimization of these molecules could lead to better anticancer therapy.

Nicolas Basse, Matthieu Montes, Xavier Marechal, Lixian Qin, Michelle Bouvier-Durand, Emilie Genin, Joelle Vidal, Bruno O. Villoutreix, Michele Rebound-Ravaux
January 14, 2010
Learn More
LinkedIn